Advertisement

Prostaglandins and Inflammation: The Cyclooxygenase Controversy

  • Olivier Morteau
Chapter

Abstract

Prostaglandins (PGs) are arachidonic acid metabolites produced by the action of the enzyme cyclooxygenase (COX). Although PGs are important mediators of inflammation in various diseases, they also are key factors in the physiological regulation of gastrointestinal and renal homeostasis. The finding that two distinct COX isoforms are responsible for PG synthesis has provided basis to the opposite actions of PGs in inflammation and homeostasis regulation. COX-1-derived PGs are thought to mediate cytoprotective actions on the gastrointestinal mucosa, whereas COX-2-derived PGs are assumed to display pro—inflammatory properties. This dichotomy has led to the development of selective inhibitors of COX-2 activity which are safer for the gastrointestinal mucosa than the classic inhibitors of both COX isoforms. However, some COX-2 anti—inflammatory properties have been recently demonstrated in several experimental models of inflammation. These studies have raised some concern about the potential adverse effects of COX-2 selective inhibitors. In addition, there is evidence that COX-1 displays pro-inflammatory properties, depending on the organ and on the stage of the inflammatory response. This review will focus on the roles of COX-1 and COX-2 in inflammation, based on studies involving pharmacologic COX inhibitors as well as COX knock-out mice, with a particular emphasis on the gastrointestinal tract.

Key words

prostaglandins cyclooxygenase nonsteroidal anti-inflammatory drugs (NSAIDs) inflammation colitis. 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abramson S. (1991): Therapy with and mechanisms of nonsteroidal anti-inflammatory drugs. Curr. Opin. Rheumatol., 3, 336–340.PubMedCrossRefGoogle Scholar
  2. Allgayer H., Deschryver K. and Stenson W. F. (1989): Treatment with 16,16’-dimethyl PGE2 before and after induction of colitis with trinitrobenzene sulfonic acid in rats decreases inflammation. Gastroenterology, 96, 1290–1300.PubMedGoogle Scholar
  3. Baik E. J., Kim E. J., Lee S. H. and Moon C. (1999): Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal death in the hippocampus. Brain Res., 843, 118–129.PubMedCrossRefGoogle Scholar
  4. Bjarnason I., Hayllar J., MacPherson A. J. and Russell A. S. (1993): Side effects of nons-teroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology, 104, 1832–1847.PubMedGoogle Scholar
  5. Bjarnason I. and MacPherson A. (1989): The changing gastrointestinal side effect profile of non-steroidal anti-inflammatory drugs. A new approach for the prevention of a new problem. Scand. J. Gastroenterol., 163 (suppl.), 56–64.CrossRefGoogle Scholar
  6. Cashman J. N. (1996): The mechanisms of action of NSAIDs in analgesia. Drugs, 52 (suppl.), 13–23.PubMedCrossRefGoogle Scholar
  7. Cohn S. M., Schloeman S., Tessner T., Seibert K. and Stenson W. F. (1997): Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J. Clin. Invest., 99, 1367–1379.Google Scholar
  8. Crofford L. J. (1999): COX-2 in synovial tissues. Osteoarthritis Cartilage, 7, 406–408.PubMedCrossRefGoogle Scholar
  9. Dewitt D. L., Meade E. A. and Smith W. L. (1993): PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal anti-inflammatory drugs. Am. J. Med., 95, 40S - 44S.PubMedCrossRefGoogle Scholar
  10. Dinchuk J. E., Car B. D., Focht R. J., Johnston J. J., Jaffee B. D., Covington M. B., Contel N. R., Eng V. M., Collins R. J., Czerniak P. M., Gorry S. A. and Trzaskos J. M. (1995): Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature, 378, 406–409.PubMedCrossRefGoogle Scholar
  11. Eberhart C. E., Coffey R. J., Radhika A., Giardiello F. M., Ferrenbach S. and Dubois R. N. (1994): Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107, 1183–1188.PubMedGoogle Scholar
  12. Ethridge R. T., Hellmich M. R., Dubois R. N. and Evers B. M. (1998): Inhibition of heat-shock protein 70 induction in intestinal cells overexpressing cyclooxygenase 2. Gastroenterology, 115, 1454–1463.PubMedCrossRefGoogle Scholar
  13. Fedorak R. N., Empey L. R., MacArthur C. and Jewell L. D. (1990): Misoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats. Gastroenterology, 98, 615–625.PubMedGoogle Scholar
  14. Futaki N., Arai I., Hamasaka Y., Takahashi S., Higuchi S. and Otomo S. (1993): Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. J. Pharm. Pharmacol., 45, 753–755.PubMedCrossRefGoogle Scholar
  15. Futaki N., Takahashi S., Yokoyama M., Arai I., Higuchi S. and Otomo S. (1994): NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins, 47, 55–59.PubMedGoogle Scholar
  16. Gavett S. H., Madison S. L., Chulada P. C., Scarborough P. E., Qu W., Boyle J. E., Tiano H. F., Lee C. A., Langenbach R., Roggli V. L. and Zeldin D. C. (1999): Allergic lung responses are increased in prostaglandin H synthase-deficient mice. J. Clin. Invest., 104, 721–732.PubMedCrossRefGoogle Scholar
  17. Gilroy D. W., Colville-NASH P. R., Willis D., Chivers J., Paul-Clark M. J. and Willoughby D. A. (1999): Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med., 5, 698–701.PubMedCrossRefGoogle Scholar
  18. Goldenberg M. M. (1999): Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin. Ther., 21, 1497–1513.PubMedCrossRefGoogle Scholar
  19. Gottlieb S. (1999): COX-2 inhibitors might be useful in cancer prevention. BMJ, 319, 1155.PubMedCrossRefGoogle Scholar
  20. Greaves M. W. and Camp R. D. (1988): Prostaglandins, leukotrienes, phospholipase, platelet activating factor, and cytokines: an integrated approach to inflammation of human skin. Arch. Dermatol. Res., 280 (suppl.), S33 — S41.PubMedCrossRefGoogle Scholar
  21. Harding P., Sigmon D. H., Alfie M. E., Huang P. L., Fishman M. C., Beierwaltes W. H. and Carretero O. A. (1997): Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet. Hypertension, 29, 297–302.PubMedCrossRefGoogle Scholar
  22. Harris R. C., Wang J. L., Cheng H. E., Zhang M. Z. and McKanna J. A. (1998): Prostaglandins in macula densa functions. Kidney Int., 67 (suppl.), S49 - S52.CrossRefGoogle Scholar
  23. Hawkey C. J. (1996): Non-steroidal anti-inflammatory drug gastropathy: causes and treatment. Scand. J. Gastroenterol., 220 (suppl.), 124–127.CrossRefGoogle Scholar
  24. Henderson W. J. jr. (1991): Eicosanoids and platelet-activating factor in allergic respiratory diseases. Am. Rev. Respir. Dis., 143, S86 — S90.PubMedGoogle Scholar
  25. Herschman H. R. (1996): Prostaglandin synthase 2. Biochim. Biophys. Acta, 1299, 125–140.Google Scholar
  26. Hoult J. R. S. and Moore P. K. (1978): Sulphasalazine is a potent inhibitor of prostaglandin 15 hydroxydehydrogenase: possible basis for therapeutic action in ulcerative colitis. Br. J. Pharmacol., 64, 6–8.PubMedCrossRefGoogle Scholar
  27. Jobin C., Morteau O., Han D. S. and Sartor R. B. (1998): Specific NF-kappa B blockade selectively inhibits tumour necrosis factor-alpha-induced COX-2 but not constitutive COX-1 gene expression in HT-29 cells. Immunology, 95, 537–543.PubMedCrossRefGoogle Scholar
  28. Jones M. K., Wang H., Peskar B. M., Levin E., Itani R. M., Sarfeh I. J. and Tarnawski A. S. (1999): Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med., 5, 1418–1423.PubMedCrossRefGoogle Scholar
  29. Kargman S. L., O’Neill G. P., Vickers P. J., Evans J. E, Mancini J. A. and Jothy S. (1995): Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res., 55, 2556–2559.PubMedGoogle Scholar
  30. Kaufmann H. J. and Taubin H. L. (1987): Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann. Intern. Med., 107, 513–516.PubMedGoogle Scholar
  31. Kirtikara K., Morham S. G., Raghow R., Laulederkind J. F., Kanekura T., Goorha S. and Ballou L. R. (1998): Compensatory prostaglandin E2 biosynthesis in cyclooxygenase 1 or 2 null cells. J. Exp. Med., 187, 517–523.PubMedCrossRefGoogle Scholar
  32. Knudsen P. J., Dinarello C. and Strom T. B. (1986): Prostaglandin posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J. Immunol., 137, 3189–3194.PubMedGoogle Scholar
  33. Kraemer S. A., Meade E. A. and DeWitt D. L. (1992): Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5’-flanking regulatory sequences. Arch. Biochem. Biophys., 293, 391–400.PubMedCrossRefGoogle Scholar
  34. Kujubu D. A., Fletcher B. S., Varnum B. C., Lim R. W. and Herschman H. R. (1991): TISIO, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem., 266, 12866–12872.Google Scholar
  35. Kujubu D. A. and Herschman H. (1992): Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J. Biol. Chem., 267, 7991–7994.PubMedGoogle Scholar
  36. Kunkel S. L., Chensue S. W. and Phan S. H. (1986): Prostaglandins as endogenous mediators of interleukin-1 production. J. Immunol., 136, 186–192.PubMedGoogle Scholar
  37. Kutchera W., Jones D. A., Matsunami N., Groden J., McIntyre T. M., Zimmerman G. A., White R. L. and Prescott S. M. (1996): Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc. Natl. Acad. Sci. USA, 93, 4816–4820.PubMedCrossRefGoogle Scholar
  38. Laine L., Harper S., Simon T., Bath R., Johanson J., Schwartz H., Stern S., Quan H. and Bolognese J. (1999): A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology, 117, 776–783.PubMedCrossRefGoogle Scholar
  39. Langenbach R., Loftin C., Lee C. and Tiano H. (1999): Cyclooxygenase knockout mice. Models for elucidating isoform-specific functions. Biochem. Pharmacol., 58, 1237–1246.PubMedCrossRefGoogle Scholar
  40. Langenbach R., Morham S. G., Tiano H. E, Loftin C. D., Ghanayem B. I., Chulada P. C., Mahler J. F., Lee C. A., Goulding E. H., Kluckman K. D., Kim H. S. and Smithies O. (1995): Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell, 83, 483–492.PubMedCrossRefGoogle Scholar
  41. Langman M. J., Jensen D. M., Watson D. J., Harper S. E., Zhao P. L., Quan H., Bolognese J. A. and Simon T. J. (1999): Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA, 282, 1929–1933.PubMedCrossRefGoogle Scholar
  42. Marcinkiewicz J. (1991): In vitro cytokine release by activated mutine peritoneal macrophages: role of prostaglandins in the differential regulation of tumor necrosis factor a, interleukin 1 and interleukin 6. Cytokine, 3, 327–332.PubMedCrossRefGoogle Scholar
  43. Masferrer J. L., Seibert K., Zweifel B. and Needleman P. (1992): Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc. Natl. Acad. Sci. USA, 89, 3917–3921.PubMedCrossRefGoogle Scholar
  44. Masferrer J. L., Zweifel B. S., Manning P. T., Hauser S. D., Leahy K. M., Smith W. G., Isakson P. C. and Seibert K. (1994): Selective inhibition of inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA, 91, 3228–3232.Google Scholar
  45. Meade E. A., Smith W. L. and Dewitt D. L. (1993): Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem., 268, 6610–6614.PubMedGoogle Scholar
  46. Mizuno H., Sakamoto C., Matsuda K., Wada K., Uchida T., Noguchi H., Akamatsu T. and Kasuga M. (1997): Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology, 112, 645–648.CrossRefGoogle Scholar
  47. Morham S. G., Langenbach R., Loftin C. D., Tiano H. F., Vouloumanos N., Jennette J. C., Mahler J. E, Kluckman K. D., Ledford A., Lee C. A. and Smithies O. (1995): Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell, 83, 473–482.PubMedCrossRefGoogle Scholar
  48. Morteau O. (1999): COX-2: promoting tolerance. Nat. Med., 5, 867–868.PubMedCrossRefGoogle Scholar
  49. Morteau 0., Morham S. G., Sellon R., Langenbach R., Smithies O. and Sartor R. B. (2000): Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J. Clin. Invest., 105, 469–478.CrossRefGoogle Scholar
  50. Nakattsugi S., Terada N., Yoshimura T., Horie Y. and Furukawa M. (1996): Effects of nime-sulide, a preferential cyclooxygenase-2 inhibitor, on carrageenan-induced pleurisy and stress--induced gastric lesions in rats. Prostaglandins Leukot. Essent. Fatty Acids, 55, 395–402.CrossRefGoogle Scholar
  51. Newberry R. D., Stenson W. E. and Lorenz R. G. (1999): Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nat. Med., 5, 900–906.PubMedCrossRefGoogle Scholar
  52. O’Banion M. K., Sadowski H. B., Winn V. and Young D. A. (1991): A serum-and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J. Biol. Chem., 266, 23261–23267.PubMedGoogle Scholar
  53. Olson G. A., Leffler C. W. and Fletcher A. M. (1985): Gastroduodenal ulceration in rabbits producing antibodies to prostaglandine. Prostaglandins, 29, 475–480.PubMedGoogle Scholar
  54. Oshima M., Dinchuk J. E., Kargman S. L., Oshima H., Hancock B., Kwong E., Trzakos J. M., Evans J. F. and Taketo M. M. (1996): Suppression of intestinal polyposis in Apc°76 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803–809.PubMedCrossRefGoogle Scholar
  55. Rachmilewitz D., Simon P. L., Schwartz L. W., Grisold D. E., Fondacaro J. D. and Wasserman M. A. (1989): Inflammatory mediators of experimental colitis in rats. Gastroenterology, 97, 326–327.PubMedGoogle Scholar
  56. Raskin J. B. (1999): Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am. J. Med., 106, 3S - 12S.PubMedCrossRefGoogle Scholar
  57. Raz A., Wyche A. and Needleman P. (1989): Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. Proc. Natl. Acad. Sci. USA, 86, 1657–1661.PubMedCrossRefGoogle Scholar
  58. Redfern J. S., Blair A. J., Lee E. and Feldman M. (1987): Gastrointestinal ulcer formation in rabbits immunized with prostaglandin E2. Gastroenterology, 93, 744–752.PubMedGoogle Scholar
  59. Reuter B. K., Asfaha S., Buret A., Sharkey K. A. and Wallace J. L. (1996): Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J. Clin. Invest., 98, 2076–2085.PubMedCrossRefGoogle Scholar
  60. Sano H., Kawahito Y., Wilder R. L., Hashiramoto A., Mukai S., Asai K., Kimura S., Kato H., Kondo M. and Hla T. (1995): Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res., 55, 3785–3789.PubMedGoogle Scholar
  61. Sartor R. B. and Powell D. W. (1991): Mechanisms of diarrhea in intestinal inflammation and hypersensitivity: immune system modulation of intestinal transport. In Field M.: Diarrheal diseases. Elsevier, New York, 75–114.Google Scholar
  62. Schiff S. J. and Rigas B. (1999): Aspirin for cancer. Nat. Med., 5, 1348–1349.CrossRefGoogle Scholar
  63. Schneider A. and Stahl R. A. K. (1998): Cyclooxygenase-2 (COX-2) and the kidney: current status and potential perspectives. Nephrol. Dial. Transplant., 13, 10–12.PubMedCrossRefGoogle Scholar
  64. Seibert K. and Masferrer J. L. (1994): Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor, 4, 17–23.PubMedGoogle Scholar
  65. Seibert K., Masferrer J. L., Zhang Y., Gregory S., Olson G., Hauser S., Leahy K., Perkins W. and Isakson P. (1995): Mediation of inflammation by cyclooxygenase-2. Agents Actions, 46 (suppl.), 41–50.Google Scholar
  66. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Perkins W., Lee L. and Isakson P. (1994): Pharmacological and biochemical demonstartion of the role of cyclooxygenase in inflammation and pain. Proc. Natl. Acad. Sci. USA, 91, 12013–12017.PubMedCrossRefGoogle Scholar
  67. Sharon P., Ligumsky M., Rachmilewitz D. and Zor U. (1978): Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology, 75, 638–640.PubMedGoogle Scholar
  68. Sheehan K. M., Sheahan K., O’Donoghue D. P., MacSweeney F., Conroy R. M., Fitzgerald D. J. and Murray F. E. (1999): The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA, 282, 1254–1257.PubMedCrossRefGoogle Scholar
  69. Shigeta J., Takahashi S. and Okabe S. (1998): Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J. Pharmacol. Exp. Ther., 286, 1383–1390.PubMedGoogle Scholar
  70. Simon L. S., Weaver A. L., Graham D. Y., Kivitz A. J., Lipsky P. E., Hubbard R. C., Isakson P. C., Verburg K. M., Yu S. S., Zhao W. W. and Geis G. S. (1999): Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA, 282, 1921–1928.PubMedCrossRefGoogle Scholar
  71. Taketo M. M. (1998): Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J. Natl. Cancer Inst., 90, 1609–1620.PubMedCrossRefGoogle Scholar
  72. Tessner T. G., Cohn S. M., Schloemann S. and Stenson W. F. (1998): Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulfate injury in mice. Gastroenterology, 115, 874–882.PubMedCrossRefGoogle Scholar
  73. Tsujii M. and Dubois R. N. (1995): Alteration in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 83, 493–501.PubMedCrossRefGoogle Scholar
  74. Wallace J. L., Bak A., McKnight W., Asfaha S., Sharkey K. A. and MacNaughton W. K. (1998): Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology, 115, 101–109.PubMedCrossRefGoogle Scholar
  75. Wen P. Z., Warden C., Fletcher B. S., Kujubu D. A., Herschman H. R. and Lusis A. J. (1993): Chromosomal organization of the inducible and constitutive prostaglandin synthase/cyclooxygenase genes in mouse. Genomics, 15, 458–460.PubMedCrossRefGoogle Scholar
  76. Xie W. L., Chipman J. G., Robertson D. L., Erikson R. L. and Simmons D. L. (1991): Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA, 88, 2692–2696.PubMedCrossRefGoogle Scholar
  77. Yamada T., Deitch E., Specian R. D., Perry M. A., Sartor R. B. and Grisham M. B. (1993): Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation, 17, 641–662.PubMedCrossRefGoogle Scholar
  78. Yokoyama C. and Tanabe T. (1989): Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem. Biophys. Res. Commun. 165, 888–894.PubMedCrossRefGoogle Scholar
  79. Zhang X., Morham S. G., Langenbach R. and Young D. A. (1999): Malignant transformation and antineoplastic actions of nonsteroidal anti-inflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J. Exp. Med., 190, 451–459.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2001

Authors and Affiliations

  • Olivier Morteau
    • 1
  1. 1.Department of Pulmonary MedicineChildren’s Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations